High Risks Adverse Events Associated with Trastuzumab Emtansine and Trastuzumab Deruxtecan for the Treatment of HER2-positive/mutated Malignancies: A Pharmacovigilance Study based on the FAERS Database

T-DXd is more likely to induce ILD/pneumonia and myelosuppression than T-DM1, whereas T-DM1 has higher risk of hepatotoxicity, cardiotoxicity, and thrombocytopenia than T-DXd. T-DM1-related hepatotoxicity may need redefinition. Clinicians may need to balance the benefits and risks of antibody-drug conjugates treatment for certain patients.